Article

Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancer

2025-06-25

Abstract excerpt

<title>Abstract</title> The combination of BRAFV600E and EGFR inhibitors benefits advanced colorectal cancer (CRC) patients, but resistance can develop through non-genetic mechanisms not fully understood. This study reveals that <italic>BRAF</italic> mutant CRC tumors undergo a tissue remodeling to resist BRAFV600E inhibitors, characterized by tumor cell mucinous differentiation and extra...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1046f5ab-e83b-5e38-ae82-1ae358210b75
DOI: 10.21203/rs.3.rs-6770441/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to BRAF inhibitory treatments requires tumor tissue remodeling and reveals targetable vulnerabilities in colorectal cancerDOI 10.21203/rs.3.rs-6770441/v1Read

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read

The Evolution of Acquired Resistance to BRAFV600E kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular RemodelingSemantic proximity Read

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancerSemantic proximity Read

Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of CancerSemantic proximity Read

BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape.Semantic proximity Read

BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities.Semantic proximity Read

Anti-angiogenesis therapy in cancer: current challenges and future perspectives.Semantic proximity Read

The past, present, and future treatment of BRAFV600-mutant metastatic colorectal cancer: A comprehensive review.Semantic proximity Read

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Semantic proximity Read

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read

Improvements in Clinical Outcomes for BRAFV600E -Mutant Metastatic Colorectal Cancer.Semantic proximity Read

BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical ApplicationsSemantic proximity Read